Author

Andrew McFadyen

Institutions: University of Toronto, Hospital for Sick Children, SickKids Foundation, Sickkids Research Institute

Observed institutions: University of Toronto, Hospital for Sick Children, Campbell Institute, Campbell Scientific (Canada), Quebec Labrador Foundation, Campbell Soup (United States), SickKids Foundation, Children's Health Queensland Hospital and Health Service, Sickkids Research Institute

ORCID: 0000-0003-0297-2586

Observed ORCID: 0000-0003-0297-2586

OpenAlex ID: A5085735800

Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance

2019 · Mehmet Umut Akyol, MPS Consensus Programme Co-Chairs, et al. · Orphanet Journal of Rare Diseases · 106

Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance

2019 · Mehmet Umut Akyol, MPS Consensus Programme Co-Chairs, et al. · Orphanet Journal of Rare Diseases · 61

What compassionate use means for gene therapies

2019 · Carolyn Riley Chapman, Kenneth I. Moch, et al. · Nature Biotechnology · 23

Gene therapy companies have an ethical obligation to develop expanded access policies

2021 · Lisa Kearns, Carolyn Riley Chapman, et al. · Molecular Therapy · 18

Ethical challenges and opportunities in the development and approval of novel therapeutics for rare diseases

2023 · Djurdja Djordjevic, Andrew McFadyen, et al. · The Journal of Medicine Access · 14

Somatic Gene Therapy Research in Pediatric Populations: Ethical Issues and Guidance for Operationalizing Early Phase Trials

2022 · Alison Bateman-House, Lesha D. Shah, et al. · Pharmaceutical Medicine · 13

Fetal Therapies and Clinical Research: Beyond Risk and Benefit

2022 · Lesha D. Shah, John Lantos, et al. · The American Journal of Bioethics · 3

A conceptual model and practical guidance for the development, administration, and evaluation of individualized therapies

2025 · Lucie Perillat, Andrew McFadyen, et al. · Frontiers in Medicine · 2

Preapproval Nontrial Access and Off-Label Use: Do They Meet Criteria for Dual-Deviation Review?

2019 · Carolyn Riley Chapman, Kelly McBride Folkers, et al. · The American Journal of Bioethics · 2

Pediatric Gene Therapy Development Can Benefit From Trial Decentralization

2022 · Cara Hunt, Andrew McFadyen, et al. · Forefront Group · 1

A Generalizable, Governance-Embedded Pathway for Assessing Patient-Level Opportunities for Genetic Medicines

2026 · David Cheerie, Amy Y. Pan, et al. · medRxiv

A conceptual model and practical guidance for the development, administration, and evaluation of individualized therapies

2025 · Lucie Perillat, Andrew McFadyen, et al. · Molecular Genetics and Metabolism

Ethical decision-making for early access to investigational medicines in rare disease

2024 · Catherine Lawrence, Ellie Matthews, et al. · Molecular Genetics and Metabolism

Works count: 13

Citation count: 242

H-index: 6

I10-index: 6